Cost-effectiveness of a chemotherapy predictive test;Analyse coût-efficacité d'un test prédictif de la chimiothérapie dans le cancer du sein (Oncotype DX®) en France

Bulletin du Cancer

Volumn 99, Issue 10, 2012, Pages 907-914

  Vataire, Anne Lise ^a   Laas, Enora ^b   Aballéa, Samuel ^a   Gligorov, Joseph ^b   Rouzier, Roman ^b   Chéreau, Élisabeth ^b  

^a CREATIV CEUTICAL   (France)

^b HÔPITAL TENON   (France)

Author keywords

Adjuvant chemotherapy; Breast cancer; Costeffectiveness analysis; Predictive test

Indexed keywords

ARTICLE; ASSAY; BREAST CANCER; CANCER RECURRENCE; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC TEST; GENETIC ANALYSIS; HEALTH CARE UTILIZATION; HUMAN; MEDICAL DECISION MAKING; MONEY; PREDICTION; PRODUCTIVITY; QUALITY ADJUSTED LIFE YEAR; RISK ASSESSMENT;

EID: 84868237303     PISSN: 00074551     EISSN: 17696917     Source Type: Journal    
DOI: 10.1684/bdc.2012.1652     Document Type: Article

References (35)

1. Chéreau E, Coutant C, Gligorov J, et al. Discordance with local guidelines for adjuvant chemotherapy in breast cancer: reasons and effect on survival. Clin Breast Cancer 2011; 11 : 46-51.
2. Early Breast Cancer Trialists' Collaborative Group. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005; 365 : 1687-717.
3. Paik S, Tang G, Shak S, et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol 2006; 24 : 3726-34.
4. Partridge AH, Burstein HJ,Winer EP. Side effects of chemotherapy and combined chemohormonal therapy in women with early-stage breast cancer. J Natl Cancer Inst Monogr 2001; 30 : 135-42.
5. Argyriou AA, Assimakopoulos K, Iconomou G, Giannakopoulou F, Kalofonos HP. Either called "chemobrain" or "chemofog", the longterm chemotherapy-induced cognitive decline in cancer survivors is real. J Pain Symptom Manage 2011; 41 : 126-39.
6. Lim CC, Devi MK, Ang E. Anxiety in women with breast cancer undergoing treatment: a systematic review. Int J Evid Based Healthc 2011; 9 : 215-35. doi: 10.1111/j.1744-1609.2011.00221.x.
7. Peugniez C, Fantoni S, Leroyer A, Skrzypczak J, Duprey M, Bonneterre J. Return to work after treatment for breast cancer: single center experience in a cohort of 273 patients. Bull Cancer 2011; 98 : E69-79.
8. Laas E, Vataire AL, Aballea S, et al. Evaluation of the costs and resource use associated with adjuvant chemotherapy for breast cancer in France. J Med Econ 2012 (ahead of print).
9. Habel Shak S, Jacobs MK, Capra A, et al. A population-based study of tumor gene expression and risk of breast cancer death among lymph node-negative patients. Breast Cancer Res 2006; 8 : R25.
10. Dowsett M, Cuzick J, Wale C, et al. Prediction of risk of distant recurrence using the 21-gene recurrence score in node-negative and node-positive postmenopausal patients with breast cancer treated with anastrozole or tamoxifen: a TransATAC study. J Clin Oncol 2010; 28 : 1829-34.
11. Liebermann N, Baehner FL, Soussan-Gutman L. Evaluation of Recurrence Score® and traditional clinicopathologic assessments in a large estrogen receptor-positive, lymph node-negative patient cohort. J Clin Oncol 2011 ; 29(suppl.) (ASCO abstract 632).
12. Paik S, Shak S, Tang G, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 2004; 351 : 2817-26.
13. Albain KS, Barlow WE, Shak S, et al. Prognostic and predictive value of the 21-gene recurrence score assay in a randomized trial of chemotherapy for postmenopausal, node-positive, estrogen receptorpositive breast cancer. Lancet Oncol 2010; 11 : 55-65.
14. Chang JC, Makris A, Gutierrez MC, et al. Gene expression patterns in formalin-fixed, paraffin-embedded core biopsies predict docetaxel chemosensitivity in breast cancer patients. Breast Cancer Res Treat 2008; 108 : 233-40.
15. Gianni L, Zambetti M, Clark K, et al. Gene expression profiles in paraffin-embedded core biopsy tissue predict response to chemotherapy in women with locally advanced breast cancer. J Clin Oncol 2005; 23 : 7265-77.
16. Simon RM, Paik S, Hayes DF. Use of archived specimens in evaluation of prognostic and predictive biomarkers. J Natl Cancer Inst 2009 ; 101 : 1446-52 (Epub 2009 Oct 8).
17. Guideline HAS, 2011.
18. Hornberger J, Cosler LE, Lyman GH. Economic analysis of targeting chemotherapy using a 21-gene RT-PCR assay in lymphnode-negative, estrogen-receptor-positive, early-stage breast cancer. Am J Manag Care 2005; 11 : 313-24.
19. Lyman GH, Cosler LE, Kuderer NM, Hornberger J. Impact of a 21-gene RT-PCR assay on treatment decisions in early-stage breast cancer: an economic analysis based on prognostic and predictive validation studies. Cancer 2007; 109 : 1011-8.
20. Klang SH, Hammerman A, Liebermann N, et al. Economic implications of 21-gene breast cancer risk assay from the perspective of an Israeli-managed health-care organization. Value Health 2010; 13 : 381-7.
21. Kondo M, Hoshi SL, Yamanaka T, Ishiguro H, Toi M. Economic evaluation of the 21-gene signature (Oncotype DX) in lymph node-negative/positive, hormone receptor-positive early-stage breast cancer based on Japanese validation study (JBCRG-TR03). Breast Cancer Res Treat 2010; 127 : 739-49.
22. Tsoi DT, Inoue M, Kelly CM, Verma S, Pritchard KI. Costeffectiveness analysis of recurrence score-guided treatment using a 21-gene assay in early breast cancer. Oncologist 2010; 15 : 457-65.
23. Hall PS, McCabe C, Stein RC, Cameron D. Economic evaluation of genomic test-directed chemotherapy for early-stage lymph nodepositive breast cancer. J Natl Cancer Inst 2012 ; 104 : 56-66 (Epub 2011 Dec 2).
24. Lamond NW, Skedgel C, Rayson D, Lethbridge L, Younis T. Cost-utility of the 21-gene recurrence score assay in nodenegative and node-positive breast cancer. Breast Cancer Res Treat 2012; 133 : 1115-23.
25. NICE report. Gene expression profiling and expanded immunohistochemistry tests to guide selection of chemotherapy regimes in breast cancer management-MammaPrint, Oncotype DX, IHC4 and Mammostrat: diagnostics assessment report, 2012 (http://guidance.nice.org.uk/DT/4/DAR/pdf/English).
26. Hornberger J, Chien R. Meta-analysis of the decision impact of the 21-gene breast cancer recurrence score in clinical practice. 33rd Annual CTRC-AACR San Antonio Breast Cancer Symposium, December 8-12, 2010, San Antonio, Abstract P6-09-09.
27. Paik S, Tang G, Shak S, et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol 2006; 24 : 3726-34.
28. Paviot BT, Bachelot T, Clavreul G, Jacquin JP, Mille D, Rodrigues JM. Impact of the chemotherapy protocols for metastatic breast cancer on the treatment cost and the survival time of 371 patients treated in three hospitals of the Rhone-Alpes region. Bull Cancer 2009; 96 : 929-40.
29. Conner-Spady BL, Cumming C, Nabholtz JM, Jacobs P, Stewart D. A longitudinal prospective study of health-related quality of life in breast cancer patients following high-dose chemotherapy with autologous blood stem cell transplantation. Bone Marrow Transplant 2005; 36 : 251-9.
30. Milne RJ, Heaton-Brown KH, Hansen P, Thomas D, Harvey V, Cubitt A. Quality-of-life valuations of advanced breast cancer by New Zealand women. Pharmacoeconomics 2006; 24 : 281-92.
31. Peasgood T, Ward SE, Brazier J. Health-state utility values in breast cancer. Expert Rev Pharmacoecon Outcomes Res 2010; 10 : 553-66.
32. Bonneterre J, Bercez C, Bonneterre ME, Lenne X, Dervaux B. Cost-effectiveness analysis of breast cancer adjuvant treatment: FEC 50 versus FEC 100 (FASG05 study). Ann Oncol 2005 ; 16 : 915-22 (Epub 2005 May 13).
33. Gligorov J, Pivot X, Naman H, et al. Prospective study of the impact of using the 21-gene recurrence score assay on clinical decision making in women with estrogen receptor-positive, HER2-negative, early stage breast cancer in France. J Clin Oncol 2012; 30 : 568.
34. Holt SDH, Bennet H, Bentelli G, et al. Cost-effectiveness evaluation of the Oncotype DX® breast cancer assay in clinical practice in the UK. Cancer Research 2011 ; 71 : suppl. 3.
35. Gluz O, Kneipe H, Christjen M, et al. Pilot phase of the randomized plan B trial: prospective comparison of molecular classification, Oncotype DX and clinical-pathological characteristics in hormonereceptor (HR) positive primary breast cancer. Cancer Research 2010 ; 70 : suppl. 2.